​
​

Jazz Pharmaceuticals (JAZZ) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Jazz Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$3.83B

Latest Revenue (Q)

$1.05B

Main Segment (Y)

Product And Services, Product Sales Net Of Deductions

Main Geography (Y)

UNITED STATES

Jazz Pharmaceuticals Revenue by Period

Jazz Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$3.83B4.78%
2022-12-31$3.66B18.26%
2021-12-31$3.09B30.91%
2020-12-31$2.36B9.34%
2019-12-31$2.16B14.32%
2018-12-31$1.89B16.82%
2017-12-31$1.62B8.79%
2016-12-31$1.49B12.32%
2015-12-31$1.32B12.95%
2014-12-31$1.17B34.44%
2013-12-31$872.42M48.88%
2012-12-31$585.98M115.21%
2011-12-31$272.28M56.68%
2010-12-31$173.78M35.29%
2009-12-31$128.45M90.26%
2008-12-31$67.51M3.39%
2007-12-31$65.30M45.58%
2006-12-31$44.86M109.20%
2005-12-31$21.44M100.00%
2004-12-31--

Jazz Pharmaceuticals generated $3.83B in revenue during NA 2023, up 4.78% compared to the previous quarter, and up 202.77% compared to the same period a year ago.

Jazz Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$1.05B3.04%
2024-06-30$1.02B13.51%
2024-03-31$901.98M-10.87%
2023-12-31$1.01B4.09%
2023-09-30$972.14M1.55%
2023-06-30$957.32M7.22%
2023-03-31$892.81M-8.16%
2022-12-31$972.12M3.35%
2022-09-30$940.65M0.83%
2022-06-30$932.88M14.64%
2022-03-31$813.72M-9.26%
2021-12-31$896.73M6.99%
2021-09-30$838.12M11.48%
2021-06-30$751.81M23.74%
2021-03-31$607.58M-8.71%
2020-12-31$665.52M10.76%
2020-09-30$600.89M6.84%
2020-06-30$562.44M5.18%
2020-03-31$534.73M-8.08%
2019-12-31$581.74M8.19%
2019-09-30$537.70M0.67%
2019-06-30$534.13M5.11%
2019-03-31$508.19M6.66%
2018-12-31$476.46M1.51%
2018-09-30$469.37M-6.22%
2018-06-30$500.48M12.57%
2018-03-31$444.61M1.88%
2017-12-31$436.40M5.96%
2017-09-30$411.86M4.43%
2017-06-30$394.39M4.88%
2017-03-31$376.05M-5.19%
2016-12-31$396.62M6.00%
2016-09-30$374.18M-1.83%
2016-06-30$381.16M13.44%
2016-03-31$336.01M-1.43%
2015-12-31$340.88M0.00%
2015-09-30$340.87M2.13%
2015-06-30$333.75M7.90%
2015-03-31$309.30M-5.74%
2014-12-31$328.14M7.03%
2014-09-30$306.58M5.27%
2014-06-30$291.23M17.95%
2014-03-31$246.92M4.73%
2013-12-31$235.77M1.56%
2013-09-30$232.16M11.48%
2013-06-30$208.25M6.12%
2013-03-31$196.24M6.82%
2012-12-31$183.70M4.67%
2012-09-30$175.51M35.49%
2012-06-30$129.54M19.49%
2012-03-31$108.41M29.78%
2011-12-31$83.54M13.98%
2011-09-30$73.29M13.51%
2011-06-30$64.57M26.90%
2011-03-31$50.88M-4.66%
2010-12-31$53.37M19.25%
2010-09-30$44.75M10.54%
2010-06-30$40.49M15.11%
2010-03-31$35.17M-8.13%
2009-12-31$38.28M24.26%
2009-09-30$30.81M-17.36%
2009-06-30$37.28M68.87%
2009-03-31$22.08M12.66%
2008-12-31$19.59M10.42%
2008-09-30$17.75M14.20%
2008-06-30$15.54M6.18%
2008-03-31$14.63M-5.45%
2007-12-31$15.48M-

Jazz Pharmaceuticals generated $1.05B in revenue during Q3 2024, up 3.04% compared to the previous quarter, and up 110.20% compared to the same period a year ago.

Jazz Pharmaceuticals Revenue Breakdown

Jazz Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Zepzelca$269.91M$246.81M$90.38M--
Total Oxybate$1.98B$1.80B$1.76B--
Xywav$958.42M$535.30M$15.26M--
Xyrem$1.02B$1.27B$1.74B$1.64B$1.40B
Vyxeos$127.98M$134.06M$121.11M$121.41M$100.83M
Defitelio/Defibrotide$194.29M$197.93M$195.84M$172.94M$149.45M
Epidiolex/Epidyolex$736.40M$463.64M---
Erwinaze And Erwinase-$69.38M$147.14M$177.47M$174.74M
Neuroscience$2.76B$2.34B$1.79B--
Oncology$873.84M$733.81M$554.46M--
Other Products$6.64M$9.80M$6.84M$17.55M$18.75M
Product And Services, Product Sales Net Of Deductions$3.64B$3.08B$2.35B--
Product And Services, Royalties And Contract Revenue$17.95M$15.24M$16.91M$26.16M$21.45M
Rylaze$281.66M$85.63M---
Sativex$16.82M$12.71M---
Sunosi$28.84M$57.91M$28.33M$3.71M-
Product And Services, Product Sales---$2.14B$1.87B
Prialt----$20.84M

Jazz Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product And Services, Product Sales Net Of Deductions (28.20%), Neuroscience (21.38%), Total Oxybate (15.32%), Xyrem (7.90%), Xywav (7.42%), Oncology (6.77%), Epidiolex/Epidyolex (5.70%), Rylaze (2.18%), Zepzelca (2.09%), Defitelio/Defibrotide (1.50%), Vyxeos (0.99%), Sunosi (0.22%), Product And Services, Royalties And Contract Revenue (0.14%), Sativex (0.13%), and Other Products (0.05%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Epidiolex/Epidyolex$251.56M$247.10M$198.72M$202.23M$188.91M$207.00M$196.22M$175.29M$157.89M$193.79M$160.38M$109.48M--------
Other Products$2.23M$2.70M$3.57M$3.42M$3.43M$3.07M$1.00M$1.63M$943.00K$1.03M$3.34M$2.64M$2.78M$1.60M$1.87M$852.00K$2.52M$4.23M$4.48M$5.17M
Xyrem$58.11M$62.18M$64.23M$159.77M$178.13M$247.50M$256.04M$269.42M$247.50M$288.76M$307.33M$334.18M$335.55M$439.27M$447.81M$446.81M$407.88M$435.35M$425.64M$413.21M
Defitelio/Defibrotide$65.82M$45.42M$47.68M$46.11M$39.08M$40.65M$49.45M$54.70M$49.49M$42.51M$57.70M$48.10M$49.62M$55.45M$50.24M$42.71M$47.43M$47.78M$37.60M$46.05M
Xywav$388.47M$368.47M$315.30M$326.56M$277.76M$281.38M$255.94M$235.03M$186.08M$182.65M$153.06M$124.16M$75.42M-------
Zepzelca$85.84M$81.05M$75.10M$70.35M$67.18M$71.97M$70.32M$68.28M$59.34M$64.84M$71.71M$55.92M$54.33M$53.44M$36.94M-----
Total Oncology$284.75M$277.31M$257.55M$252.21M$228.89M---------------
Sativex$4.59M$6.38M$2.73M$2.81M$7.10M$4.72M$3.22M$4.14M$4.74M$4.65M$6.10M$1.96M--------
Product And Services, Product Sales Net Of Deductions$989.71M$964.14M$842.10M$946.99M$884.22M$967.53M$935.77M$928.30M$809.84M$892.88M$834.25M$748.34M$603.53M$661.30M$596.95M-----
Vyxeos$34.31M$43.01M$32.02M$34.06M$36.70M$30.27M$30.07M$33.89M$33.76M$34.76M$34.69M$31.45M$33.16M$30.99M$30.82M$26.57M$32.72M$31.52M$29.58M$31.36M
Rylaze---$101.69M$85.93M$80.97M$73.51M$72.95M$54.22M$64.95M$20.67M---------
Sunosi-------$12.97M$15.88M$14.93M$19.25M$12.12M$11.61M$8.71M$9.12M$8.58M$1.92M$2.73M$987.00K-
Total Oxybate---$486.33M$455.89M$528.88M$511.98M$504.45M$433.58M$471.42M$460.40M$458.35M$410.97M-------
Neuroscience-----$740.60M$711.41M$696.84M$612.09M$684.79M$646.12M$581.91M$422.57M-------
Oncology-----$223.86M$223.35M$229.82M$196.80M$207.07M$184.78M$163.79M$178.18M-------
Product And Services, Royalties And Contract Revenue-----$4.60M$4.89M$4.58M$3.88M$3.85M$3.87M$3.47M$4.05M$4.21M$3.94M$4.23M$4.52M$5.21M$5.38M$10.71M
Erwinaze And Erwinase-----------$28.31M$41.07M$56.58M$20.14M$32.68M$37.73M$54.92M$34.02M$27.62M
Product And Services, Product Sales---------------$558.20M$530.21M$576.53M$532.32M$523.42M

Jazz Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product And Services, Product Sales Net Of Deductions (45.71%), Xywav (17.94%), Total Oncology (13.15%), Epidiolex/Epidyolex (11.62%), Zepzelca (3.96%), Defitelio/Defibrotide (3.04%), Xyrem (2.68%), Vyxeos (1.58%), Sativex (0.21%), and Other Products (0.10%).

Jazz Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
Europe$239.64M$230.16M$175.21M$150.20M$125.91M
UNITED STATES$3.37B$2.82B$2.14B$1.97B$1.73B
Other Countries$49.36M$43.84M$43.82M$46.24M$37.44M

Jazz Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (92.10%), Europe (6.55%), and Other Countries (1.35%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Other Countries$23.98M$17.07M$22.41M$13.28M$16.80M$10.70M$12.79M$13.76M$12.11M$7.29M$10.16M$13.64M$12.06M$13.99M$6.70M$8.44M$14.69M$9.34M$10.30M$16.68M
Europe$77.32M$82.16M$71.36M$59.33M$65.90M$57.81M$60.02M$60.78M$61.03M$65.62M$70.73M$47.27M$47.23M$49.98M$45.78M$37.90M$41.56M$43.24M$35.04M$36.52M
UNITED STATES$953.67M$924.59M$808.21M$884.71M$810.12M$903.62M$867.84M$858.34M$740.58M$823.82M$757.23M$690.90M$548.29M$601.55M$548.41M$516.10M$478.48M$529.16M$492.37M$480.93M

Jazz Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (90.40%), Europe (7.33%), and Other Countries (2.27%).

Jazz Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JAZZJazz Pharmaceuticals$3.83B$1.05B
INCYIncyte$3.70B$962.99M
BMRNBioMarin Pharmaceutical$2.42B$733.87B
UTHRUnited Therapeutics$2.33B$748.90M
EXELExelixis$1.83B$478.06M
ALNYAlnylam Pharmaceuticals$1.83B$420.15M
ARGXargenx SE$1.23B$401.00M
TECHBio-Techne$1.16B$289.46M
HALOHalozyme Therapeutics$829.25M$290.08M
RAREUltragenyx Pharmaceutical$434.25M$147.03M
APLSApellis Pharmaceuticals$366.28M$176.57M
DNLIDenali Therapeutics$330.53M-
LEGNLegend Biotech$285.14M$93.99M
ASNDAscendis Pharma$266.72M$95.89M
BPMCBlueprint Medicines$249.38M$128.18M
PTGXProtagonist Therapeutics$60.00M$4.67M
LQDALiquidia$17.49M$4.45M
INBXInhibrx Biosciences$1.80M-
VRDNViridian Therapeutics$314.00K$86.00K
PCVXVaxcyte--
DICEDICE Therapeutics--
LRMRLarimar Therapeutics--

JAZZ Revenue FAQ

What is Jazz Pharmaceuticals’s yearly revenue?

Jazz Pharmaceuticals's yearly revenue for 2023 was $3.83B, representing an increase of 4.78% compared to 2022. The company's yearly revenue for 2022 was $3.66B, representing an increase of 18.26% compared to 2021. JAZZ's yearly revenue for 2021 was $3.09B, representing an increase of 30.91% compared to 2020.

What is Jazz Pharmaceuticals’s quarterly revenue?

Jazz Pharmaceuticals's quarterly revenue for Q3 2024 was $1.05B, a 3.04% increase from the previous quarter (Q2 2024), and a 8.52% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.02B, a 13.51% increase from the previous quarter (Q1 2024), and a 6.95% increase year-over-year (Q2 2023). JAZZ's quarterly revenue for Q1 2024 was $901.98M, a -10.87% decrease from the previous quarter (Q4 2023), and a 1.03% increase year-over-year (Q1 2023).

What is Jazz Pharmaceuticals’s revenue growth rate?

Jazz Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 23.91%, and for the last 5 years (2019-2023) was 77.36%.

What are Jazz Pharmaceuticals’s revenue streams?

Jazz Pharmaceuticals's revenue streams in c 22 are Zepzelca, Total Oxybate, Xywav, Xyrem, Vyxeos, Defitelio/Defibrotide, Epidiolex/Epidyolex, Neuroscience, Oncology, Other Products, Product And Services, Product Sales Net Of Deductions, Product And Services, Royalties And Contract Revenue, Rylaze, Sativex, and Sunosi. Zepzelca generated $269.91M in revenue, accounting 2.09% of the company's total revenue, up 9.36% year-over-year. Total Oxybate generated $1.98B in revenue, accounting 15.32% of the company's total revenue, up 9.87% year-over-year. Xywav generated $958.42M in revenue, accounting 7.42% of the company's total revenue, up 79.05% year-over-year. Xyrem generated $1.02B in revenue, accounting 7.90% of the company's total revenue, down -19.38% year-over-year. Vyxeos generated $127.98M in revenue, accounting 0.99% of the company's total revenue, down -4.54% year-over-year. Defitelio/Defibrotide generated $194.29M in revenue, accounting 1.50% of the company's total revenue, down -1.84% year-over-year. Epidiolex/Epidyolex generated $736.4M in revenue, accounting 5.70% of the company's total revenue, up 58.83% year-over-year. Neuroscience generated $2.76B in revenue, accounting 21.38% of the company's total revenue, up 18.22% year-over-year. Oncology generated $873.84M in revenue, accounting 6.77% of the company's total revenue, up 19.08% year-over-year. Other Products generated $6.64M in revenue, accounting 0.05% of the company's total revenue, down -32.20% year-over-year. Product And Services, Product Sales Net Of Deductions generated $3.64B in revenue, accounting 28.20% of the company's total revenue, up 18.27% year-over-year. Product And Services, Royalties And Contract Revenue generated $17.94M in revenue, accounting 0.14% of the company's total revenue, up 17.77% year-over-year. Rylaze generated $281.66M in revenue, accounting 2.18% of the company's total revenue, up 228.93% year-over-year. Sativex generated $16.82M in revenue, accounting 0.13% of the company's total revenue, up 32.41% year-over-year. Sunosi generated $28.84M in revenue, accounting 0.22% of the company's total revenue, down -50.20% year-over-year.

What is Jazz Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Jazz Pharmaceuticals was Product And Services, Product Sales Net Of Deductions. This segment made a revenue of $3.64B, representing 28.20% of the company's total revenue.